UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 10, 2012

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Alexion Pharmaceuticals, Inc.

File No. 0-27756 - CF#27809

Alexion Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on January 4, 2012.

Based on representations by Alexion Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 2.1 through January 4, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Sonia Barros Special Counsel